Recent Company News

• 07:30 AM ET Jun 15, 2026
  

  SanBio upgraded to hold at Jefferies (¥1210.0000, 0)

• 02:38 AM ET Jun 15, 2026
  

  SanBio reports Q1 net income attributable (¥836M) vs FactSet (¥821.7M) [2 est, (¥1.20)-(443.5M)] (¥1210.0000, 0)

• 02:38 AM ET May 21, 2026
  

  SanBio launches sales of AKUUGO intracerebral transplant injection for treatment for traumatic brain injury today (¥1518.0000, 0)

• 02:54 AM ET May 20, 2026
  

  Japan Central Social Insurance Medical Council confirms price for SanBio's AKUUGO injection at ¥72.7M (¥1429.0000, 0)

• 11:12 PM ET May 12, 2026
  

  SanBio raises FY guidance following approval of proposed drug price for AKUUGO (¥2530.0000, +293)

• 02:57 AM ET Apr 23, 2026
  

  SanBio expects to begin in Japan sales of Akuugo in H1, first dose of Akuugo in H2 this year (¥2123.0000, 0)

• 02:37 AM ET Mar 17, 2026
  

  SanBio reports FY net income attributable (¥3.84B) vs FactSet (¥3.95B) [4 est, (¥4.24-3.32B)] (¥1985.0000, 0)

• 06:27 PM ET Jan 05, 2026
  

  SanBio upgraded to neutral from sell at Citi (¥1637.0000, 0)

• 01:01 AM ET Dec 16, 2025
  

  Street Takeaways - SanBio 9M/Q3 earnings (¥1620.0000, -45)

• 01:35 AM ET Dec 15, 2025
  

  SanBio reports 9M net income attributable (¥2.71B) vs year-ago (¥2.15B) (¥1665.0000, 0)